To explore the difference in curative effect of two foam sclerosing agents, polidocanol and sodium morrhuate, in the treatment of varicose veins under DSA guidance.

A retrospective analysis of the medical records of 73 patients with varicose veins of the lower extremities admitted to the Department of Minimally Invasive Intervention, Guangzhou Panyu Central Hospital from January 2018 to December 2018. They were divided into two groups according to different treatment methods (36 cases in group A, 37 cases in group B), and polidocanol (group A) and sodium morrhuate (group B) were used for DSA guided foam sclerotherapy. The contrast of different sclerosing agents were compared in terms of clinical success rate, quality of life improvement, complications, and surgical costs.

There were no significant differences between the two groups of patients in age, course of disease, preoperative clinical disease classification, VCSS scores and CIVIQ scores (P > 0.05). The clinical disease classification of the two groups improved within 1 year after treatment, and during the annual follow-up, the treatment success rate of group A was 82.9%, and the partial success rate was 8.6%, while the treatment success rate of group Bwas 60.0%, and the partial success rate was 25.7%. There was a statistically significant difference in the clinical success rate between the two groups (χ² = 7.583, P < 0.05). Within 1 year of follow-up after treatment, the three efficacy evaluation scales of the two groups of patients were improved compared with those of preoperative. Among them, the improvement of group A was better than that of group B in the CEAP grading evaluation at 1 week, 1 month and 1 year after the operation, the VCSS grading evaluation at 1 week after the operation, and the CIVIQ scores in the next week and one month after the operation. The postoperative adverse reactions of the two groups were mainly pain and pigmentation, and the incidence of group B was higher than that of group A. The average hospitalization cost of group B patients was lower than that of group A. There were statistical differences between the two groups (P < 0.01).

The average hospitalization cost of sodium morrhuate group was lower than that of polidocanol group, but during the 1-year follow-up period, the success rate of polidocanol treatment is higher than that of sodium morrhuate, including subjective feelings are improved more obviously, and adverse reactions are less. Therefore, polidocanol is more effective than sodium morrhuate in the treatment of varicose veins, and it is worthy of clinical application.